The new board members are world-class scientists and clinical researchers:

• Martin Farlow, Professor of Neurology and Emeritus of Neurology at the Indiana University School of Medicine in Indianapolis;
• Reisa Sperling, a neurologist focused on the detection and treatment of Alzheimer’s disease and Professor in Neurology at Harvard Medical School; and
• Michael Weiner, a researcher in the field of Alzheimer’s disease with over 50 years of experience and Professor in Radiology, Medicine, Psychiatry and Neurology at the University of California, San Fransisco.

Paul Brennan, NervGen president and CEO, commented on the appointments.

“We now have a full complement of world-class experts to guide both our Alzheimer’s preclinical studies and clinical trials leveraging biomarkers, neuroimaging and cognitive testing,” he said.

“The combined knowledge of this advisory board will help us maximize the probability of success,” he added, “as we advance the development of NVG-291 in a Phase 1b Alzheimer’s disease clinical trial.”

Along with the four existing board members, the scientific advisory board will continue to guide NervGen as it prepares for the 2022 clinical trials of its NVG-291 compound in Alzheimer’s patients.

NVG-291 modulates the downstream activity of inhibitory molecules in the central nervous system.

“The expansion of our Alzheimer’s Disease Scientific Advisory Board with such impressive scientific and clinical leaders in the field speaks to the opportunity that our drug provides,” remarked Dr. Daniel Mikol, NervGen’s Chief Medical Officer.

“[W]e have the opportunity,” he added, “to create a completely new treatment paradigm as a neurorestorative therapy for Alzheimer’s disease.”

NervGen Pharma Corp. is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases.

NervGen Pharma Corp. (NGEN) is trading at $1.64 per share as of 3:28 pm ET.